SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3...
Hence then, the article about atyr pharma inc s atyr failed drug trial spurs securities lawsuit hagens berman was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman )
Also on site :
- Denver Fire Department responds to 3-alarm fire at intersection of Leetsdale Drive and S. Forest Street
- China’s special envoy meets Maduro (VIDEO)
- Trial to begin for police officer charged in delayed response to Uvalde school shooting